Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.91 USD | +0.82% | -1.60% | -45.38% |
Mar. 20 | ILJIN SNT Delivers a Letter to Aurinia Pharmaceuticals | CI |
Mar. 07 | Aurinia Pharmaceuticals Insider Sold Shares Worth $711,094, According to a Recent SEC Filing | MT |
Business Summary
Number of employees: 300
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Therapeutic Drugs
100.0
%
| 134 | 100.0 % | 176 | 100.0 % | +30.95% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
90.0
%
| 102 | 76.4 % | 158 | 90.0 % | +54.17% |
Japan
10.0
%
| 31 | 23.5 % | 18 | 10.0 % | -44.24% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Michael Martin
FOU | Founder | 52 | 93-06-15 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 19-04-28 |
Robert Foster
FOU | Founder | 65 | 93-06-15 |
Joseph Miller
DFI | Director of Finance/CFO | 50 | 20-04-26 |
Compliance Officer | 42 | 13-12-31 | |
Matthew Donley
COO | Chief Operating Officer | 55 | 19-07-17 |
Sue Evans
LAW | General Counsel | - | 13-12-31 |
Fran Lynch
SAM | Sales & Marketing | - | 20-02-24 |
Scott Habig
PRN | Corporate Officer/Principal | 64 | 22-07-14 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Foster
FOU | Founder | 65 | 93-06-15 |
R. MacKay-Dunn
BRD | Director/Board Member | 73 | 19-06-25 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 19-04-28 |
Jill Leversage
BRD | Director/Board Member | 67 | 19-11-12 |
Jeffrey Bailey
BRD | Director/Board Member | 62 | 23-08-17 |
Michael Martin
FOU | Founder | 52 | 93-06-15 |
Karen Smith
BRD | Director/Board Member | 56 | 23-08-17 |
David Jaynee
BRD | Director/Board Member | 67 | 15-05-25 |
Director/Board Member | 44 | 21-06-13 | |
Daniel Billen
CHM | Chairman | 70 | 19-04-28 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 144,617,762 | 133,849,462 ( 92.55 %) | 0 | 92.55 % |
Company contact information
Aurinia Pharmaceuticals, Inc.
14315 – 118 Avenue Suite 140
T5L 4S6, Edmonton
+250 744 2487
http://www.auriniapharma.comSector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.38% | 704M | |
-2.31% | 103B | |
+0.56% | 95.71B | |
+1.69% | 22.02B | |
-17.37% | 20.9B | |
-9.30% | 17.85B | |
-41.01% | 16.21B | |
-14.85% | 15.52B | |
+3.21% | 13.86B | |
+33.54% | 12.04B |
- Stock Market
- Equities
- AUPH Stock
- Company Aurinia Pharmaceuticals Inc.